Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Axsome Therapeutics (AXSM) over the last 3 years, with Q2 2025 value amounting to -$1.0 million.

  • Axsome Therapeutics' Tax Provisions changed N/A to -$1.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$915000.0, marking a year-over-year decrease of 16911.76%. This contributed to the annual value of $85000.0 for FY2024, which is 9114.58% down from last year.
  • Axsome Therapeutics' Tax Provisions amounted to -$1.0 million in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Tax Provisions peaked at $2.6 million during Q1 2023, and registered a low of -$1.0 million during Q2 2025.
  • For the 3-year period, Axsome Therapeutics' Tax Provisions averaged around $4666.7, with its median value being -$478500.0 (2023).
  • The largest annual percentage gain for Axsome Therapeutics' Tax Provisions in the last 5 years was 12500.0% (2024), contrasted with its biggest fall of 12500.0% (2024).
  • Axsome Therapeutics' Tax Provisions (Quarter) stood at -$340000.0 in 2023, then soared by 125.0% to $85000.0 in 2024, then plummeted by 1276.47% to -$1.0 million in 2025.
  • Its Tax Provisions was -$1.0 million in Q2 2025, compared to $85000.0 in Q4 2024 and -$340000.0 in Q4 2023.